AGTC to Host Analyst and Investor Day on June 22, 2015 in New York

GAINESVILLE, Fla., June 15, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it will host an Analyst and Investor Day in New York City on June 22, 2015. AGTC management will be joined by renowned industry leaders to discuss AGTC's clinical development programs and the promise of ophthalmic gene therapy.

A live webcast of the presentation will be accessible by visiting A replay will be available on AGTC's website for at least 30 days following the event.


Date: June 22, 2015

Time: 8:30 a.m. – 12:00 p.m. (Registration beginning at 8:00 a.m. ET)


  • Bill Hauswirth, Ph.D., Professor of Ophthalmology, University of Florida College of Medicine
  • Mark Pennesi, M.D., Ph.D., Assistant Professor of Ophthalmology, Casey Eye Institute, Oregon Health and Science University
  • Joe Carroll, Ph.D., Professor in Ophthalmology, Co-Director Advanced Ocular Imaging Program, Medical College of Wisconsin
  • Steve Rose, Ph.D., Chief Research Officer, Foundation Fighting Blindness
  • Sue Washer, President and CEO, AGTC
  • Jeff Chulay, M.D., VP and Chief Medical Officer, AGTC
  • Dave Knop, Ph.D., Senior Director, Process Development, AGTC

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC is also using its gene therapy expertise to expand into disease indications with large market opportunity such as wet AMD.

Forward Looking Statements

This release contains forward-looking statements that reflect AGTC's plans, estimates, assumptions and beliefs. Forward-looking statements include information concerning possible or assumed future results of operations, business strategies and operations, preclinical and clinical product development and regulatory progress, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors, including, without limitation, those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014, as filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this release. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

CONTACT: David Carey Lazar Partners Ltd. T: (212) 867-1768 Corporate Contact: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204

Source:Applied Genetic Technologies